热门资讯> 正文

XTL生物制药宣布1比4 ADS比例变更

2026-03-21 04:19

Xtl生物制药(XTLB) 0

XTL Biopharmaceuticals (XTLB) will change its ADS ratio from 1:100 to 1:400 effective March 25, 2026.
The move is equivalent to a 1-for-4 reverse ADS split for shareholders.
No fractional ADSs will be issued; proceeds from fractional sales will be distributed in cash.

More on XTL Biopharmaceuticals

XTL announces receipt of staff delisting letter from Nasdaq
Financial information for XTL Biopharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。